Cochrane · systematic review · CD013365

Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma

Ernst, M, Oeser, A, Besiroglu, B, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library

HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 7 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Summary of findings for the efficacy and safety of CAR T‐cell therapy for people with relapsed or refractory DLBCL

Population: people with relapsed or refractory DLBCL
7 questions
OutcomeEffectEvidenceStatus / GRADE
Overall survival (
no estimate extracted8 studies · 567 participantsVery low
Downgraded: risk of bias, imprecision, inconsistency
Quality of life (
no estimate extracted2 studies · 294 participantsVery low
Downgraded: risk of bias, imprecision, inconsistency
Any adverse events (
no estimate extracted5 studies · 550 participantsVery low
Downgraded: risk of bias, imprecision, inconsistency
Any serious adverse events (
no estimate extracted4 studies · 281 participantsVery low
Downgraded: risk of bias, imprecision, inconsistency
Cytokine release syndrome (
no estimate extracted11 studies · 675 participantsVery low
Downgraded: risk of bias, imprecision, inconsistency
Progression‐free survival (
no estimate extracted9 studies · 575 participantsVery low
Downgraded: risk of bias, imprecision, inconsistency
Complete response (
no estimate extracted13 studies · 620 participantsVery low
Downgraded: risk of bias, imprecision, inconsistency